Volition (VolitionRx) is a diagnostics company developing blood tests for cancer and other serious diseases, based on detecting epigenetic changes in nucleosomes — protein-DNA structures shed by diseased cells into the bloodstream. Volition's tests use standard immunoassay formats (ELISA or automated immunoassay), making them cheaper and easier to deploy than sequencing-based liquid biopsy approaches. Volition organizes its business around four product lines built on the same underlying Nu.Q nucleosome platform: Nu.Q Vet, Nu.Q NETs, Nu.Q Cancer, and Nu.Q Discover. Nu.Q Vet is the most commercially advanced, offering a cancer screening blood test for dogs sold through distributors including Antech, IDEXX, and Fujifilm Vet Systems in over 20 countries. Nu.Q NETs targets diseases driven by excessive neutrophil extracellular trap formation, most notably sepsis, and is the only CE-marked assay for this purpose; it is being evaluated across hospital networks in Europe. Nu.Q Cancer focuses on lung cancer screening, particularly distinguishing malignant from benign pulmonary nodules. Nu.Q Discover sells research kits and contract services to pharma and biotech companies for epigenetic drug development. Volition's core business model is to license its technology to large established diagnostic companies rather than build its own commercial infrastructure — mirroring the Antech licensing deal it executed in veterinary diagnostics. Current revenue comes from kit sales, milestone payments, and early licensing fees, but Volition's long-term revenue model is built around royalties from partners deploying Nu.Q tests at scale on their existing analyzer platforms and distribution networks.